Ultragenyx Pharmaceutical Inc. - Common Stock (RARE)
29.51
-1.52 (-4.90%)
NASDAQ · Last Trade: Jul 12th, 2:19 AM EDT
Detailed Quote
Previous Close
31.03
Open
30.64
Bid
28.24
Ask
28.41
Day's Range
29.03 - 30.88
52 Week Range
29.03 - 60.37
Volume
5,681,361
Market Cap
2.09B
PE Ratio (TTM)
-5.027
EPS (TTM)
-5.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,984,511
Chart
About Ultragenyx Pharmaceutical Inc. - Common Stock (RARE)
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of rare genetic disorders. The company specializes in creating novel treatments targeting serious diseases caused by genetic mutations, particularly those that affect critical metabolic pathways. With a strong emphasis on research and development, Ultragenyx strives to bring hope and improved quality of life to patients living with rare conditions by harnessing cutting-edge science and technology to address unmet medical needs. Read More
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
NOVATO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,731 restricted stock units of the company’s common stock to 26 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
NOVATO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's chief executive officer, will participate in a fireside at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 10:00 a.m. ET.
